drugset

drugset / Trial / NCT00303108

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

NCT00303108 ↗

Phase 2 Completed 136 enrolled US Oncology Research Ortho Biotech, Inc. · collab Tibotec Pharmaceutical Limited · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).

Timeline

Start: 2005-12
Primary completion: 2010-03
Completion: 2011-06

Publications

Collea RP, Kruter FW, Cantrell JE, George TK, Kruger S, Favret AM, Lindquist DL, Melnyk AM, Pluenneke RE, Shao SH, Crockett MW, Asmar L, O'Shaughnessy J. Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Ann Oncol. 2012 Oct;23(10):2599-2605. doi: 10.1093/annonc/mds052. Epub 2012 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Pegylated liposomal doxorubicin	Unknown	30 mg/m2	Intravenous
Subject	Trastuzumab	Monoclonal antibody	4 mg/kg	Intravenous

Indications